Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Salmedix Inc.
Karyopharm Scores $48M Series B To Advance Early Cancer Compounds
The Massachusetts biotech has remained well-funded despite shying away from venture capital investors and seeking funds from private investors.
Financings Of The Fortnight: Thiel Looks To Bridge The Pre-Venture Capital Funding Gap For Biotech
Plus news on recent financing activity by Alcresta, Alder Biopharmaceuticals, H.I.G Capital and Supernus Pharmaceuticals.
H.I.G. BioVentures Closes Second Fund Above Target, Team Upbeat
H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.
Hamade's Compass Leads to Aberdare
In the eyes of one West Coast device VC, Sami Hamade has the perfect resume to be a venture capitalist. He spent over a decade at Guidant creating or funding new start-up ventures, both internally and externally. He's sat on boards, demonstrated market savvy and established connections with all the right venture firms and laboratories in Silicon Valley. Now Hamade is prepared to do the job at Aberdare Ventures, a small but highly regarded venture firm based in San Francisco.
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.